Videos

Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.

Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.

Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.

Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.

Selecting candidates for radioligand therapy requires more than a positive PSMA scan, and the panel details how tracer avidity, disease volume, and sequencing with hormonal therapy affect outcomes.

A high-risk, newly diagnosed patient's PSMA PET results reshape surgical planning, nerve-sparing decisions, and the choice between surgery and radiation for definitive local therapy.

Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.

Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.

Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.

Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.

Delayed diagnosis and skipped nodal staging worsen penile cancer outcomes, according to Luis G. Medina, MD.

Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.

Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.

Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.

A rising PSA after treatment discontinuation prompts a PSMA PET that reveals a solitary rib lesion, testing how much confidence clinicians place in a single indeterminate finding.

Adoption of PSMA PET still varies by practice setting, and the panel discusses how visualized disease reshapes conversations with patients accustomed to tracking PSA values alone.

Daniel Spratt, MD, outlines the validation standards urologists should expect before adopting AI-based tools, where AI-driven digital pathology is headed, and his key takeaway from the benchmarking data.

Daniel Spratt, MD, explains how he layers MMAI results onto NCCN risk groups and how he manages discordant results in both directions.

Daniel Spratt, MD, reviews how closely MMAI-predicted 10-year distant metastasis and prostate cancer–specific mortality tracked observed STAR-CAP outcomes, including among patients treated with surgery.

Daniel Spratt, MD, explains what the STAR-CAP cohort is, what an MMAI risk estimate represents, and why calibration benchmarking differs from clinical validation.

Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.

Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.

Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.

Martin T. King, MD, PhD, looks ahead to micro-boost radiation, SBRT, and open questions about sexual and urinary quality of life that could reshape how rectal spacers are used.

No periprocedural adverse events and no new late safety signals: Martin T. King, MD, PhD, explains why 3-year data reassure him about rectal spacer use in appropriately selected patients.

Martin T. King, MD, PhD, compares his 3-year hyaluronic acid spacer results with prior hydrogel data and walks through the practical factors, sculpting, apical placement, reversibility, that shape his own product choice.

As IMRT and image-guided techniques push precision to its limits, Martin T. King, MD, PhD, argues rectal spacers still earn their place by widening the margin between prostate and rectum.

Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.

Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.

Martin T. King, MD, PhD, unpacks why fewer grade 2 or higher GI events with rectal spacing can mean fewer colonoscopies, less rectal bleeding, and meaningful quality-of-life gains for patients weighing their radiation options.